Skip to Content
Global News Select

Selecta Biosciences Says FDA Puts Clinical Hold on SEL-302 Trial, Shares Lower

By Stephen Nakrosis

 

Shares of biotechnology company Selecta Biosciences Inc. are trading lower in Wednesday's late-session, after the company said the U.S. Food and Drug Administration placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 to treat patients with methylmalonic acidemia.

The company said SEL-302 consists of MMA-101 plus ImmTOR.

Selecta Biosciences also said on Nov. 23 it received a letter from the FDA "issuing a clinical hold in order to obtain additional information on the chemistry, manufacturing and controls related to the MMA-101 product candidate."

"Patient safety is our primary concern, and we are committed to addressing the FDA's questions regarding CMC as expeditiously as possible," said Carsten Brunn, president and chief executive.

At 5:35 p.m. ET, shares of Selecta Biosciences were trading 13.2% lower at $2.76 a share. Volume at the time topped 150,000 shares.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

November 24, 2021 18:08 ET (23:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.